90Y-Tabituximab barzuxetan (90Y-OTSA101-DTPA) is a radiolabeled drug based on an anti-FZD10 (Frizzled Homolog 10) antibody and has been developed as novel cancer therapy for synovial sarcoma. 90Y-Tabituximab barzuxetan was designated as an orphan drug for treatment of soft tissue sarcoma by European Commission and FDA respectively.
90Y- Tabituximab barzuxetan is presently in Phase 0 clinical trial.